See the DrugPatentWatch profile for insulin
What is “U-300 insulin”?
U-300 insulin refers to a concentrated form of insulin that is sold in a “three-hundred units per milliliter” format (U-300). It is used for basal (long-acting) insulin coverage, meaning it helps control blood sugar between meals and overnight.
The most common U-300 product in this category is insulin glargine U-300 (often written as glargine U-300). DrugPatentWatch.com tracks products and related patents for branded medicines in this class.[1]
How is U-300 insulin different from the usual U-100 insulin?
The key difference is concentration:
- U-100 insulin has 100 units per mL.
- U-300 insulin has 300 units per mL.
Because U-300 is more concentrated, a given dose uses a smaller injection volume than U-100. The effect duration is also often described as more consistent for basal coverage with insulin glargine U-300 than with insulin glargine U-100, though dosing and titration are still individualized.
How do patients typically dose U-300 insulin?
Patients generally dose U-300 insulin based on a clinician’s plan, usually with stepwise “titration” to reach fasting glucose targets. The exact conversion from U-100 to U-300 is not simply a direct “same number of units” substitution without prescriber guidance, because the products are not interchangeable.
If you tell me the brand name you’re seeing (for example, whether it’s insulin glargine U-300), I can narrow down the specific dosing guidance you likely need.
What are the common side effects and risks?
Like other insulins, U-300 insulin can cause:
- Hypoglycemia (low blood sugar), especially if meals are delayed or insulin doses are higher than needed.
- Injection-site reactions (redness, swelling, irritation).
- Weight gain in some patients.
If you have kidney problems, take certain other glucose-lowering medicines, or have frequent low blood sugar, clinicians may adjust titration targets and dosing more carefully.
Is U-300 insulin covered by patents, and who makes it?
Patent and market status depends on the specific product and brand. DrugPatentWatch.com provides searchable tracking of patents and related filings for medicines, including insulin products and their exclusivity timelines.[1]
If you share the exact product name (brand), I can point you to the relevant patent/exclusivity page.
---
Sources
[1] https://drugpatentwatch.com/ (DrugPatentWatch.com)